Custom service
Computer-aided Enzyme Design
Designing an active site around the chemistry you want.
De novo enzyme design is one of the hardest problems in the field, and the honest framing is that activity comes from catalysis, not from binding. A designed pocket that positions the substrate well may still be a poor enzyme because it does not stabilise the transition state. The design process therefore starts from the transition state, not from the substrate.
The workflow is iterative by nature. The desired chemistry is specified — bond formed or broken, cofactor used, stereochemistry required — and a theozyme, an ideal active-site geometry that stabilises the transition state, is built first. Rosetta or comparable design tools then fit protein scaffolds around that geometry, and each designed sequence is scored for pocket packing, folding stability and solubility before anything is made.
Most designed enzymes are weak on the first pass, and the numbers say so plainly: kcat/KM improvements of orders of magnitude come from the experimental optimisation cycles that follow, not from the initial design. Directed evolution around a designed active site is part of the workflow, not an admission of failure — the design provides the starting point, and evolution provides the catalytic proficiency.
Computer-aided design fits a defined reaction that no natural enzyme performs, or an existing enzyme whose specificity must be redirected at the active site.
It is the wrong tool for improving an enzyme's thermal stability — that is stability engineering — and for cases where a natural enzyme with the desired activity probably exists and simply has not been found. Sequence and metagenome searching is the cheaper first move.
Every design is delivered with its kinetic parameters, the verification that the measured activity is the intended chemistry, and the design rationale connecting the active-site geometry to the outcome. Designs that showed no activity are documented, since they inform the next cycle.
Service Highlights
- Transition-state first. Theozyme design precedes scaffold selection, because stabilising the transition state is the actual design goal.
- Scaffold ranking. Candidate scaffolds scored for pocket packing, predicted stability and solubility before synthesis.
- Cofactor-aware design. PLP, metal ions, flavins and other cofactors modelled explicitly, including their pre-organised positioning.
- Kinetic acceptance criteria. Designs judged on kcat, KM and kcat/KM against the specified target, not on substrate binding alone.
- Evolution handoff. Weak designs enter a directed evolution cycle focused on the active-site second shell.
- Mechanistic verification. Activity confirmed as the intended chemistry by substrate and product analysis, not by a generic readout.
How the work runs
Reaction specification
Bond chemistry, cofactor, stereochemistry and target kinetics defined; feasibility assessed against known precedents.
Theozyme design
Ideal active-site geometry built around the transition state, with catalytic residues positioned.
Scaffold search and design
Protein backbones fitted to the geometry; sequences designed and scored.
Expression and screening
Designed variants expressed and screened for the intended activity at single-point and combination level.
Kinetic characterisation
Active variants characterised by kcat, KM and mechanism verification.
Optimisation cycle
Directed evolution on second-shell residues; iterated until the kinetic target is reached.
Specifications & timeline
- Chemistries
- Hydrolysis, transfer, redox and bond-forming reactions; cofactor-dependent chemistry supported
- Tools
- Rosetta design suite, docking, molecular dynamics, QM reference calculations
- Screening scale
- 10–100 designed variants per cycle
- Kinetics
- kcat, KM, kcat/KM by steady-state assays
- Timeline
- 4–10 weeks per design and optimisation cycle
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.